Actavis’s Forest acquisition has piqued industry interest in Teva Pharmaceutical. Bloomberg reports that the Maxim Group thinks that the Actavis move has boosted “prospects that Teva could be acquired next.” Among Maxim’s reasons: a new CEO, a shrinking executive board, and a cost-cutting strategy.
Teva would not comment on Bloomberg’s story.
